Nivolumab (Opdivo, Bristol-Myers Squibb) plus ipilimumab (Yervoy, Bristol-Myers Squibb) is indicated for 'the treatment of adults with mismatch repair deficient or microsatellite instability-high colorectal cancer' for 'first-line treatment of unresectable or metastatic colorectal cancer'.
The dosage schedule is available in the summary of product characteristics for nivolumab and the summary of product characteristics for ipilimumab.
Nivolumab costs £2,633 for a 24‑mg vial and ipilimumab costs £3,750 for a 50‑mg vial (excluding VAT; BNF online accessed March 2025).
The company has commercial arrangements. These make nivolumab and ipilimumab available to the NHS with a discount. The size of the discounts is commercial in confidence.